PRDX1 and fatty liver disease: Further analysis showed no significant differences in the baseline age, gender, degree of obesity, insulin resistance, hepatic steatosis and circulating Prdx1 levels between the primary cohort and the validation cohort (p > 0.05) (Table 3), suggesting that both cohorts were homogeneous.